Kbc Group Nv Regeneron Pharmaceuticals, Inc. Transaction History

Kbc Group Nv

$32.2 Billion
Q1 2025

A detailed history of Kbc Group Nv transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 149,440 shares of REGN stock, worth $90.2 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

149,440

Previous 136,647 9.36%

Holding current value

$90.2 Million

Previous $97.3 Million 2.63%

% of portfolio

0.29%

Previous 0.27%

46 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	BUY	$634.14 - $744.83 $8.11 Million - $9.53 Million	12,793 Added 9.36%	149,440 $94.8 Million
Q4 2024 Jan 22, 2025	BUY	$701.85 - $1046.91 $71.7 Million - $107 Million	102,198 Added 296.66%	136,647 $97.3 Million
Q3 2024 Nov 06, 2024	BUY	$1024.09 - $1201.76 $7,168 - $8,412	7 Added 0.02%	34,449 $36.2 Million
Q2 2024 Jul 17, 2024	BUY	$883.2 - $1071.19 $166,041 - $201,383	188 Added 0.55%	34,442 $36.2 Million
Q1 2024 May 08, 2024	SELL	$902.69 - $993.35 $28.2 Million - $31.1 Million	-31,273 Reduced 47.73%	34,254 $33 Million
Q4 2023 Feb 13, 2024	SELL	$775.18 - $881.7 $4.37 Million - $4.96 Million	-5,631 Reduced 7.91%	65,527 $57.6 Million
Q3 2023 Feb 15, 2024	SELL	$692.45 - $844.37 $3.28 Million - $3.99 Million	-4,730 Reduced 6.63%	66,585 $54.8 Million
Q2 2023 Feb 15, 2024	BUY	$700.03 - $830.35 $6.46 Million - $7.67 Million	9,235 Added 14.88%	71,315 $51.2 Million
Q2 2023 Jul 28, 2023	SELL	$700.03 - $830.35 $3.17 Million - $3.76 Million	-4,531 Reduced 5.99%	71,158 $51.1 Million
Q1 2023 Feb 14, 2024	SELL	$680.49 - $826.97 $22.6 Million - $27.5 Million	-33,233 Reduced 30.47%	75,846 $62.3 Million
Q1 2023 May 04, 2023	BUY	$680.49 - $826.97 $9.37 Million - $11.4 Million	13,766 Added 22.23%	75,689 $62.2 Million
Q4 2022 Feb 14, 2024	BUY	$705.89 - $766.39 $18 Million - $19.6 Million	25,544 Added 30.58%	109,079 $78.7 Million
Q3 2022 Feb 15, 2024	SELL	$573.97 - $724.32 $1.98 Million - $2.5 Million	-3,447 Reduced 5.26%	62,080 $42.8 Million
Q3 2022 Nov 08, 2022	SELL	$573.97 - $724.32 $12 Million - $15.2 Million	-20,929 Reduced 25.26%	61,923 $42.7 Million
Q2 2022 Feb 14, 2024	SELL	$548.35 - $738.84 $1.76 Million - $2.38 Million	-3,217 Reduced 3.71%	83,535 $49.4 Million
Q2 2022 Jul 26, 2022	SELL	$548.35 - $738.84 $2.14 Million - $2.88 Million	-3,900 Reduced 4.5%	82,852 $49 Million
Q1 2022 Feb 14, 2024	SELL	$595.12 - $698.43 $86.6 Million - $102 Million	-145,494 Reduced 62.65%	86,752 $60.6 Million
Q1 2022 May 06, 2022	SELL	$595.12 - $698.43 $86.6 Million - $102 Million	-145,494 Reduced 62.65%	86,752 $60.6 Million
Q4 2021 Feb 14, 2024	BUY	$543.48 - $670.97 $90.6 Million - $112 Million	166,719 Added 254.43%	232,246 $147 Million
Q4 2021 Feb 03, 2022	BUY	$543.48 - $670.97 $47.8 Million - $59 Million	87,909 Added 60.91%	232,246 $147 Million
Q3 2021 Nov 10, 2021	BUY	$574.03 - $680.96 $7.17 Million - $8.51 Million	12,496 Added 9.48%	144,337 $87.4 Million
Q2 2021 Aug 11, 2021	SELL	$472.8 - $558.54 $7.5 Million - $8.87 Million	-15,873 Reduced 10.75%	131,841 $73.6 Million
Q1 2021 Apr 26, 2021	BUY	$446.73 - $548.2 $1.54 Million - $1.89 Million	3,441 Added 2.39%	147,714 $69.9 Million
Q4 2020 Feb 10, 2021	BUY	$478.3 - $607.98 $7.4 Million - $9.4 Million	15,462 Added 12.0%	144,273 $69.7 Million
Q3 2020 Oct 28, 2020	BUY	$544.75 - $658.21 $33 Million - $39.9 Million	60,606 Added 88.86%	128,811 $72.1 Million
Q2 2020 Aug 10, 2020	BUY	$493.32 - $643.92 $17.7 Million - $23.1 Million	35,842 Added 110.75%	68,205 $42.5 Million
Q1 2020 May 04, 2020	SELL	$336.18 - $494.43 $3.87 Million - $5.69 Million	-11,501 Reduced 26.22%	32,363 $15.8 Million
Q4 2019 Feb 11, 2020	SELL	$274.13 - $376.51 $353,079 - $484,944	-1,288 Reduced 2.85%	43,864 $16.5 Million
Q3 2019 Nov 07, 2019	BUY	$273.46 - $318.39 $12.3 Million - $14.3 Million	44,821 Added 13541.09%	45,152 $12.5 Million
Q2 2019 Dec 03, 2019	SELL	$299.6 - $414.82 $14.5 Million - $20 Million	-48,297 Reduced 99.32%	331 $104,000
Q2 2019 Jul 30, 2019	BUY	$299.6 - $414.82 $14.5 Million - $20 Million	48,297 Added 14591.24%	48,628 $0
Q1 2019 Dec 03, 2019	SELL	$372.08 - $439.57 $14.3 Million - $16.9 Million	-38,385 Reduced 99.15%	331 $136,000
Q1 2019 May 10, 2019	BUY	$372.08 - $439.57 $14.3 Million - $16.9 Million	38,385 Added 11596.68%	38,716 $0
Q4 2018 Dec 03, 2019	SELL	$335.82 - $403.04 $4.66 Million - $5.59 Million	-13,880 Reduced 97.67%	331 $124,000
Q4 2018 Jan 31, 2019	BUY	$335.82 - $403.04 $4.66 Million - $5.59 Million	13,880 Added 4193.35%	14,211 $5.31 Million
Q3 2018 Dec 03, 2019	SELL	$351.14 - $408.51 $4.16 Million - $4.84 Million	-11,857 Reduced 97.28%	331 $134,000
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $4.16 Million - $4.84 Million	11,857 Added 3582.18%	12,188 $0
Q2 2018 Dec 03, 2019	SELL	$284.6 - $344.99 $1.78 Million - $2.15 Million	-6,237 Reduced 94.96%	331 $114,000
Q2 2018 Aug 03, 2018	BUY	$284.6 - $344.99 $1.78 Million - $2.15 Million	6,237 Added 1884.29%	6,568 $0
Q1 2018 Dec 03, 2019	SELL	$315.82 - $393.78 $1.87 Million - $2.33 Million	-5,922 Reduced 94.71%	331 $114,000
Q1 2018 May 09, 2018	BUY	$315.82 - $393.78 $1.87 Million - $2.33 Million	5,922 Added 1789.12%	6,253 $0
Q4 2017 Dec 03, 2019	SELL	$358.63 - $469.95 $2.42 Million - $3.17 Million	-6,754 Reduced 95.33%	331 $124,000
Q4 2017 Feb 07, 2018	BUY	$358.63 - $469.95 $2.42 Million - $3.17 Million	6,754 Added 2040.48%	7,085 $0
Q3 2017 Dec 03, 2019	SELL	$431.38 - $504.0 $3.66 Million - $4.28 Million	-8,485 Reduced 96.25%	331 $148,000
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $3.66 Million - $4.28 Million	8,485 Added 2563.44%	8,816 $0
Q2 2017 Dec 03, 2019	BUY	N/A	331	331 $163,000

Others Institutions Holding REGN

# of Institutions

1,475

Shares Held

87.4M

Call Options Held

1.51M

Put Options Held

1.42M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $64.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account